

## Case Investigation Form Coronavirus Disease (COVID-19) Version 8



- 1) The Case Investigation Form (CIF) is meant to be administered as an interview by a health care worker or any personnel of the DRU. This is not a self-administered questionnaire.
- 2) Please be advised that DRUs are only allowed to obtain **1 copy of accomplished CIF** from a patient.
- 3) Please fill out all blanks and put a check mark on the appropriate box. Never leave an item blank (write N/A). Items with \* are required fields. All dates must be in MM/DD/YYYY format.

Disease Reporting Unit*			DRU Region and Province		PhilHealth No.*						
Name of Interviewer			Contact Number of Intervie	Date of Interview (MM/DD/YYYY)*							
Name of Informant (if app	licable)		Relationship	Contact Number of Informant							
If aviating and		olicable (New case	'	date outcome		Update dis	•				
If existing case		olicable (Unknown symptoms	'	date case classification date lab result		Others, spe	posure / travel his	tory			
(check all that apply)*	•	health status	•	date chest imaging findings	ш	Others, spi	ecity.				
Type of Client				☐ Close Contact	☐ For RT-	PCR Testing	(Not a Case of C	lose Contact)			
Testing Category/Subgroup			· · · · · · · · · · · · · · · · · · ·	B		□ G	П Н П				
Part 1. Patient Informatio											
1.1. Patient Profile			T		T						
Last Name*			First Name (and Suffix)*	Middle Name*							
Birthday (MM/DD/YYYY)*			Age*	Sex* ☐ Male ☐ Female							
Civil Status			Nationality*								
Occupation			Works in a closed setting?	☐ Yes	☐ No ☐ Unknown						
	ss in the Dhi	innings and Cont		Idress of institution if patient I		ottinas soo		WII			
	ss in the Phi	Street/Puro	•	Barangay*	ives ili ciosea si	_	-				
House No./Lot/Bldg.*		Street/Puro	K/SILIO .	Barangay .		Municipal	iity/City ·	<u>.y</u> .			
<b>D</b> • *		51	N (0 A C I )								
Province*		Home Phon	e No. (& Area Code)	Cellphone No.*	Email Address						
12.5	Id 1 a		- (16 d166	d d 1							
	dress and C		n (if different from current a	1		N 4	lite (Cite)				
House No./Lot/Bldg.		Street/Puro	K/SitiO	Barangay		Municipality/City					
Durantara		Harris Black	- N - (0 A C - d - )	Callabara Na		Const. Asha	l				
Province Ho			e No. (& Area Code)	Cellphone No.	Email Address						
1.4 Cumant Manua	۸	a and Cantast Inf									
1.4. Current Work	place Addres	s and Contact Inf	ormation		Municipal	lity/City					
Lot/Bldg. Street				Barangay	balangay						
Province Name of Wo			arknlace		Email Add	Iracc					
TTOVITICE		Ivallic of vv	rkplace Phone No./Cellphone No.								
1.5. Special Population (indicate further details on exposure and travel history in Part 3)											
Health Care Worker*		•	tion of health facility:	<i>y</i>				No			
Returning Overseas Filipin		es, Country of or		and OFW: 🗆 OF	n-OFW No						
Foreign National Traveler*		es, Country of or									
Locally Stranded Individua			ality, & Province of origin					No			
APOR / Local Traveler*											
☐ Yes specify institution type: and name: ☐ No							No				
Lives in Closed Settings*  (e.g. prisons, residential facilities, retirement communities, care homes, camps, etc.)											
Indigenous Person*		es, specify group	-				No				
Part 2. Case Investigation											
2.1. Consultation I		2	1 11 - 6-1 10 11	(2.2.2.(= = 4.0.0.0.)*							
Have previous COVID-19 r			Yes, Date of First Consult	(MM/DD/YYYY)*				No			
Name of facility where firs			61 10 10 10 1								
2.2. Disposition at Time of Report* (Provide name of hospital/isolation/quarantine facility)											
Admitted in hospital Date and Time admitted in hospital Date and Time isolated/guarantined in facility.											
<ul> <li>□ Admitted in isolation/quarantine facility</li> <li>□ In home isolation/quarantine</li> <li>□ Date and Time isolated/quarantined at home</li> </ul>											
☐ In home isolation/quarantine Date and Time isolated/quarantined at home ☐ Discharged to home If discharged: Date of Discharge (MM/DD/YYYY)* ☐ Others:											
2.3. Health Status				☐ Mild ☐ Mo	derate	☐ Severe		 Critical			
2.4. Case Classifica			□ Suspect		nfirmed		OVID-19 Case				
2.5. Clinical Inform		о препам т	🗆 зазрест			110II-CC	2 1 1 2 Case				
Date of Onset of Illness (MM/DD/VVVV)*											
Signs and Symptoms (Check all that apply)  Comorbidities (Check all that apply if present)											
Asymptomatic	□ None		☐ Gast	trointestinal							
☐ Fever °C	, , , , , , , , , , , , , , , , , , ,			☐ Hypertension ☐ Genito-urinary							
□ Cough				☐ Diabetes ☐ Neurological Disease							
☐ General weakness		niting		☐ Heart Disease							
☐ Fatigue		rhea		☐ Lung Disease		Others					
<ul><li>☐ Headache</li><li>☐ Myalgia</li></ul>		red Mental Status	, w/o any identified cause)		Yes, LMP (MM/						
<ul><li>☐ Myalgia</li><li>☐ Sore throat</li></ul>			w/o any identified cause)	High-risk pregnancy?	Yes	□ No					
☐ Coryza		ers, specify		Was diagnosed to have Severe	Acute Respirator	ry Illness?	☐ Yes	□ No			

Chest imaging findings suggestive of COVID-19																	
Date done																	
Date done																	
									dist								
	☐ Lung ultras	brund	- rending			ple bilateral ground glass opacities, often rounded in morphology, w/ peripheral & lower lung dist.							, uist.				
1	☐ None	Juilu		•		bund: Thickened pleural lines, B lines, consolidative patterns with or without air bronchograms											
26.1	Other findings, specify  2.6. Laboratory Information																
				n Callantian (8)	M 4 /DD //	2000											
Have tested p			es, date of specime	n Collection (M	<i>א</i> לטט/אוי	YYY)*				,					)		
RT-PCR before? * Laboratory* No. of previous RT-PCR swabs done																	
Date collected	d* Date releas	ed L	aboratory*		Type of t			_					Resu				_
						-PCR (OPS)			Antigen to	est; Pro	vide reaso	n below		Pending			gative
						-PCR (NPS)	and NDC)		Antibody			_		Positive		Equ	uivocal
						-PCR (OPS a	and NPS)		Antibody	test				Others:			
						hers:			A 4: 4-	D				D1!	_	NI -	
							PCR (OPS)  Antigen test; Provide reason below:  Pending								•	gative	
						-PCR (NPS) -PCR (OPS a	and NDC)		Antibody	tost		_		Positive		Equ	uivocal
							allu INF3)		Antibody	ıesı				Others:			
2.7. Outcome/Condition at Time of Report*																	
	-		•	¬	1						¬ - · · ·		.1 4				
☐ Active (cu	rrently admitte	d/isolat	ion/quarantine)	☐ Recovered,	date of i	recovery (	MM/DD/YY	'YY)* <sub>.</sub>			□ Died, da	ite of de	eath (MM	I/DD/YYYY)*			
If died,	Imn	nediate	Cause:					Α	ntecedent (	Cause:							
cause of deat	h* Und	lerlying	Cause:	<u> </u>				C	ontributory	Cond	itions:						
ī.																	
PART 3. Conta	act Tracing: Ex	posure	and Travel History														
			ble and/or confirm	ed COVID-19 ca	se 14 da	ays before	the onset	Tr	☐ Yes, d	ate of	last contac	t (MM/	DD/YYYY)	*			
, ,			ptomatic, 14 days b			•			⊒ les, u □ No				Jnknown			_	
_			a known COVID-19					_	Yes, Ir	ternat	tional		es, Local				
	•		matic, 14 days before		,				□ No	ittiia	lionai		•	exposure			
	1	зупірсо	illatic, 14 days bere			el dates:	1011:				F=====		JIIKIIUWII				
If Internation											From:			To:			
country of ori			1		ongoing				ransmission		□ Yes	1_		□ No			
Airline/Sea ve	essel		Flight/Vessel N	umber			Date of de	parti	ure ( <i>MM/Dl</i>	D/YYYY	)	Date o	of arrival	in PH <i>(MM)</i>	DD/YY	(YY)	
If Local Travel	l, specify travel	places (	Check all that appl	y, provide nam	e of facil	lity, addre:	ss, and inc	lusiv	e travel dat	es in N	1M/DD/YY	Y)					
Dlace Visited			Name of D	200			Address				Inclusive T	ravel Da	ates	With on	going	COV	ID-19
Place Visited			Name of Pl	ace	(Re	gion, Prov	ince, Muni	cipal	lity/City)	From	:	To:		Commun	ity Tra	ansmi	ission?
☐ Health F	acility													☐ Yes			No
☐ Closed S	ettings													☐ Yes			No
☐ School	0													☐ Yes			No
☐ Workpla	ICO.													☐ Yes			No
														☐ Yes			No
☐ Social G	atnering													☐ Yes			No
☐ Others														☐ Yes		<u> </u>	No
	ort Service, spec																
Airline / Sea v	essel / Bus line /	Train	Flight / Vessel / Bus	s No. Pla	ace of Or	igin	Departure	e Dat	e (MM/DD/	YYYY)	De:	stination	1	Date of Arri	/al (M	M/DE	D/YYYY)
- If symptoma	itic, provide nar	nes and	contact numbers	of persons who	, Na	me ( <i>Use ti</i>	me (Use the back page if needed) Contact Number										
			r to onset of illness	•											_		
	•		nd contact numbers		0					-				_			
			ecimen was submit	•													
until this date	•	, -1		8													
Appendix 1. COVID-19 Case Definitions																	
SUSPECT PROBABLE																	
A) A person who meets the clinical AND epidemiological criteria  A) A patient who meets the clinical criteria (on the left) AND is contact of a probable or																	
- Clinical criteria: confirmed case,									•			cluster	of cases v	vhich had ha	ıd at le	east o	ne
,								confirmed identified within that cluster									
2) Acute onset of ANY THREE OR MORE of the following signs or							B) A suspect case (on the left) with chest imaging showing findings suggestive of COVID-19										
symptoms; fever, cough, general weakness/fatigue, headache,							disease. Typical chest imaging findings include (Manna, 2020):										
myalgia, sore throat, coryza, dyspnea, anorexia / nausea/ vomiting, diarrhea, altered mental status. AND							Chest radiography: hazy opacities, often rounded in morphology, with peripheral and lower lung distribution.										
ularrilea, altereu mentai Status. AND							lung distribution  — Chest CT: multiple hilateral ground glass opacities often rounded in morphology, with										
Epidemiological criteria							Chest CT: multiple bilateral ground glass opacities, often rounded in morphology, with  peripheral and lower lung distribution.										
Epidemiological criteria     Residing/working in an area with high risk of transmission of the virus							peripheral and lower lung distribution										
(e.g closed residential settings and humanitarian settings, such as							Lung ultrasound: thickened pleural lines, B lines (multifocal, discrete, or confluent),     consolidative patterns with or without air bronchograms.										
camp and camp-like setting for displaced persons), any time w/in the						consolidative patterns with or without air bronchograms  C) A person with recent onset of anosmia (loss of smell), ageusia (loss of taste) in the absence of											
14 days prior to symptoms onset <b>OR</b>						any other identified cause											
Residing in or travel to an area with community transmission anytime							D) Death, not otherwise explained, in an adult with respiratory distress preceding death AND										
w/in the 14 days prior to symptoms onset; OR							who was a contact of a probable or confirmed case or epidemiologically linked to a cluster										
3) Working in health setting, including w/in the health facilities and w/in							which has had at least one confirmed case identified with that cluster										
	-		the 14 days prior to s														
CONFIRMED																	
		•	ratory illness (SARI:														
infection with history of fever or measured fever of ≥ 38°C; cough with							A person with <b>laboratory confirmation of COVID-19 infection</b> , irrespective of clinical signs and symptoms.										
onset w/in the last 10 days; and who requires hospitalization)									irrespe	ctive o	t clinical sig	gns and s	symptoms	i.			

## Appendix 2. Testing Category / Subgroup

- A Individuals with severe/critical symptoms and relevant history of travel/contact
- B Individuals with mild symptoms, relevant history of travel/contact, and considered vulnerable; vulnerable populations include those elderly and with preexisting medical conditions that predispose them to severe presentation and complications of COVID-19
- C Individuals with mild symptoms, and relevant history of travel and/or contact
- D Individuals with no symptoms but with relevant history of travel and/or contact or high risk of exposure. These include:
- D1 Contact-traced individuals
- D2 Healthcare workers, who shall be prioritized for regular testing in order to ensure the stability of our healthcare system
- D3 Returning Overseas Filipino (ROF) workers, who shall immediately be tested at port of entry
- Filipino citizens in a specific locality within the Philippines who have expressed
   intention to return to their place of residence/home origin (Locally Stranded Individuals) may be tested subject to the existing protocols of the IATF
- Frontliners indirectly involved in health care provision in the response against COVID-19 may be tested as follows:
- Those with high or direct exposure to COVID-19 regardless of location may be tested up to once a week. These include: (1) Personnel manning the Temporary Treatment and Quarantine Facilities (LGU and Nationally-managed); (2) Personnel serving at the COVID-19 swabbing center; (3) Contact tracing personnel; and (4) Any personnel conducting swabbing for COVID-19 testing
- Those who do not have high or direct exposure to COVID-19 but who live or work in Special Concern Areas may be tested up to every two to four weeks. These include the following: (1) Personnel manning Quarantine Control Points, including those from Armed Forces of the Philippines, Bureau of Fire Protection; (2) National / Regional / Local Risk Reduction and Management Teams; (3) Officials from any local government / city / municipality health office (CEDSU, CESU, etc.); (4) Barangay Health Emergency Response Teams and barangay officials providing barangay border control and performing COVID-19-related tasks; (5) Personnel of Bureau of Corrections and Bureau of Jail Penology & Management; (6) Personnel manning the One-Stop-Shop in the Management of ROFs; (7) Border control or patrol officers, such as immigration officers and the Philippine Coast Guard; and (8) Social workers providing amelioration and relief assistance to communities and performing COVID-19-related tasks
- F Other vulnerable patients and those living in confined spaces. These include but are not limited to: (1) Pregnant patients who shall be tested during the peripartum period; (2) Dialysis patients; (3) Patients who are immunocompromised, such as those who have HIV/AIDS, inherited diseases that affect the immune system; (4) Patients undergoing chemotherapy or radiotherapy; (5) Patients who will undergo elective surgical procedures with high risk for transmission; (6) Any person who have had organ transplants, or have had bone marrow or stem cell transplant in the past 6 months; (7) Any person who is about to be admitted in enclosed institutions such as jails, penitentiaries, and mental institutions.

- G Residents, occupants or workers in a localized area with an active COVID-19 cluster, as identified and declared by the local chief executive in accordance with existing DOH Guidelines and consistent with the National Task Force Memorandum Circular No. 02 s.2020 or the Operational Guidelines on the Application of the Zoning Containment Strategy in the Localization of the National Action Plan Against COVID-19 Response. The local chief executive shall conduct the necessary testing in order to protect the broader community and critical economic activities and to avoid a declaration of a wider community quarantine.
- H Frontliners in Tourist Zones:
- H1 All workers and employees in the hospitality and tourism sectors in El Nido, Boracay, Coron, Panglao, Siargao and other tourist zones, as identified and declared by the Department of Tourism. These workers and employees may be tested once every four (4) weeks.
- H2 All travelers, whether of domestic or foreign origin, may be tested at least once, at their own expense, prior to entry into any designated tourist zone, as identified and declared by the Department of Tourism.
- 1 All workers and employees of manufacturing companies and public service providers registered in economic zones located in Special Concern Areas may be tested regularly.

#### J Economy Workers

- J1 Frontline and Economic Priority Workers, defined as those 1) who work in high priority sectors, both public and private, 2) have high interaction with and exposure to the public, and 3) who live or work in Special Concerns Areas, may be tested every three (3) months. These include but not limited to:
  - Transport and Logistics: drivers of taxis, ride hailing services, buses, public transport vehicle, conductors, pilots, flight attendants, flight engineers, rail operators, mechanics, servicemen, delivery staff, water transport workers (ferries, inter-island shipping, ports)
  - **Food Retails**: waiters, waitress, bar attendants, baristas, chefs, cooks, restaurant managers, supervisors
  - **Education**: teachers at all levels of education and other school frontliners such as guidance counselors, librarians, cashiers
  - Financial Services: bank tellers
  - Non-Food Retails: cashiers, stock clerks, retail salespersons
  - **Services:** hairdressers, barbers, manicurists, pedicurists, massage therapists, embalmers, morticians, undertakers, funeral directors, parking lot attendants, security guards, messengers
  - Construction: construction workers including carpenters, stonemasons, electricians, painters, foremen, supervisors, civil engineers, structural engineers, construction managers, crane/tower operators, elevator installers, repairmen
  - Water Supply, Sewerage, Waster Management: plumbers, recycling/ reclamation workers, garbage collectors, water/wastewater engineers, janitors, cleaners
  - **Public Sector**: judges, courtroom clerks, staff and security, all national and local government employees rendering frontline services in special concern areas
  - Mass Media: field reporters, photographers, cameramen
- All employees **not covered above are not required to undergo testing but are encouraged to be tested every quarter.** Private sector employers are highly
  encouraged to send their employees for regular testing at the employers' expense
  in order to avoid lockdowns that may do more damage to their companies.

## Appendix 3. Severity of the Disease

#### MILD

Symptomatic patients presenting with fever, cough, fatigue, anorexia, myalgias; other non-specific symptoms such as sore throat, nasal congestion, headache, diarrhea, nausea and vomiting; loss of smell (anosmia) or loss of taste (ageusia) preceding the onset of respiratory symptoms with **NO signs of pneumonia or hypoxia** 

#### MODERATE

- Adolescent or adult with clinical signs of non-severe pneumonia (e.g. fever, cough, dyspnea, respiratory rate (RR) = 21-30 breaths/minute, peripheral capillary oxygen saturation (SpO2) >92% on room air)
- Child with clinical signs of non-severe pneumonia (cough or difficulty of breathing and fast breathing [ < 2 months: > 60; 2-11 months: > 50; 1-5 years: > 40] and/or chest indrawing)

#### SEVERE

- Adolescent or adult with clinical signs of severe pneumonia or severe acute respiratory infection as follows: fever, cough, dyspnea, RR>30 breaths/minute, severe respiratory distress or SpO2 < 92% on room air</li>
- 2. Child with clinical signs of pneumonia (cough or difficulty in breathing) plus at least one of the following:
  - a. Central cyanosis or SpO2 < 90%; severe respiratory distress (e.g. fast breathing, grunting, very severe chest indrawing); general danger sign: inability to breastfeed or drink, lethargy or unconsciousness, or convulsions
  - Fast breathing (in breaths/min): < 2 months: > 60; 2-11 months: > 50; 1-5 years: > 40.

## CRITICAL

Patients manifesting with acute respiratory distress syndrome, sepsis and/or septic shock:

## 1. Acute Respiratory Distress Syndrome (ARDS)

a. Patients with onset within 1 week of known clinical insult (pneumonia) or new or worsening respiratory symptoms, progressing infiltrates on chest X-ray or chest CT scan, with respiratory failure not fully explained by cardiac failure or fluid overload

## 2. Sepsis

- a. Adults with life-threatening organ dysfunction caused by a dysregulated host response to suspected or proven infection. Signs of organ dysfunction include altered mental status, difficult or fast breathing, low oxygen saturation, reduced urine output, fast heart rate, weak pulse, cold extremities or low blood pressure, skin mottling, or laboratory evidence of coagulopathy, thrombocytopenia, acidosis, high lactate or hyperbilirubinemia
- b. Children with suspected or proven infection and > 2 age-based systemic inflammatory response syndrome criteria (abnormal temperature [> 38.5 °C or < 36 °C); tachycardia for age or bradycardia for age if < 1year; tachypnea for age or need for mechanical ventilation; abnormal white blood cell count for age or > 10% bands), of which one must be abnormal temperature or white blood cell count.

### 3. Septic Shock

- a. Adults with persistent hypotension despite volume resuscitation, requiring vasopressors to maintain MAP > 65 mmHg and serum lactate level >2mmol/L
- b. Children with any hypotension (SBP < Sth centile or > 2 SD below normal for age) or two or three of the following: altered mental status; bradycardia or tachycardia (HR < 90 bpm or > 160 bpm in infants and heart rate < 70 bpm or > 150 bpm in children); prolonged capillary refill (> 2 sec) or weak pulse; fast breathing; mottled or cool skin or petechial or purpuric rash; high lactate; reduced urine output; hyperthermia or hypothermia.



# PATIENT CONSENT AND AUTHORIZATION FOR RELEASE OF INFORMATION VIA EMAIL OR THROUGH REPRESENTATIVE

You have agreed to provide ARC Hospitals with your email address and / or authorized a representative to receive physical copies of your medical results. Please be aware that there are some limits on what and when we can email you and / or release through your representative.

Please note: We do not receive emails from patients.

Please tell us which email address you wish us to use. Don't forget to notify us of any changes to your email address.

### (Email address)

- If you intend to receive our emails, please be sure to update your address book and check you junk/spam folder.
- Please be aware there are privacy risks in using email:
  - Email is not secure. While we try to protect our emails we cannot guarantee the security and confidentiality of any email you receive from us. As the email is sent across the Internet it could be intercepted and read.
  - O Email is easy to forge, easy to forward to other people and may exist forever.
  - If you use a work email, your employer may have a right to inspect and archive emails sent from their systems. We recommend you avoid using a work email.

Please indicate below the name of your authorized representative. He / She should be able to provide an official identification card upon request of our staff.

(Name of Representative)

## PATIENT ACKNOWLEDGMENT, AGREEMENT AND RELEASE OF LIABILITY

I have read and fully understand this consent and release form. I understand the risks involved with using email, my representative and I accept those risks. I agree that ARC Hospitals shall not be responsible for any personal injury including death, and/or privacy breach (outside the control of ARCH) or other damages as a result of my choice to receive emails from ARC Hospitals and I release ARC Hospitals from any liability from data privacy law breach and its legal implications relating to communicating with me by email.

Ans	swer the following questions,	, please tick the appropriate box:					
. Р	urpose of Swabbing:						
	☐ Influenza-like illness	☐ For travel purposes					
	☐ Company Protocol	☐ For surgical operation/childbirth					
	☐ Locally Stranded Individuals	Authorized Person Outside Residence					
	☐ Back to work requirement	Others:					
2.	Have you ever been swabbe	ed before?					
	□NO	□YES					
3.	CERTIFICATION. If your answ 3 and 4 questions.	roceed to the RT-PCR TESTING wer is YES, please answer numbers ken? (Please indicate date of					
	collection)						
4.	What was the result of you	r previous RT-PCR?					
	POSITIVE (SARS-CoV-2						
	☐ NEGATIVE (SARS-CoV-2	? Viral RNA not detected)					
	RT-PCR C	ERTIFICATION					
be th f	elief that all of the informa lese legal documents are c	mit all my data for the Regional Epidemiology or any notifiable diseases					
	SIGNATURE OVER PRINT	TED NAME OF PATIENT					

DATE AND TIME OF COLLECTION